Program
ASP388B
A development code.
Its studies are mostly in Squamous Cell Carcinoma of Head and Neck, led by Astellas Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 11 open or running | phase 2since Jul 23, 2026 | Jul 23, 2026 | Feb 28, 2030phase 2 · NCT07730021 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 23, 2026First study: phase 2 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT07730021 · 392 planned · United States, Japan
Ahead
- Feb 28, 2030Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07730021
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07730021Squamous Cell Carcinoma of Head and Neck · United States, Japan | 2 | Recruiting | Feb 28, 2030 | 392 |
How it is read
Names in the registry
- “ASP388B”, 1 entry
Codes read as this program: ASP388B.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.